Top Markets
Coin of the day
TetraLogic Pharmaceuticals Corporation TetraLogic Pharmaceuticals Corporation

TetraLogic Pharmaceuticals Corporation

TLOG
Peringkat dalam Saham #42528
TetraLogic Pharmaceuticals Corporation operates as a clinical-stage... TetraLogic Pharmaceuticals Corporation operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on identifying and advancing small-molecule treatments for cancer and infectious diseases. The company's development pipeline features two key clinical-stage drug candidates: birinapant and SHAPE. Birinapant, a small molecule, functions as a Second Mitochondrial Activator of Caspases (SMAC) mimetic, promoting programmed cell death, or apoptosis, in compromised cells. SHAPE, another proprietary compound, is a histone deacetylase (HDAC) inhibitor intended for topical administration to address early-stage cutaneous T-cell lymphoma. Furthermore, TetraLogic Pharmaceuticals has a research collaboration with the Walter and Eliza Hall Institute of Medical Research to explore the application of SMAC-mimetics, including birinapant, in treating infectious diseases. Founded in 2001 as Gentara Corporation, the company adopted its current name, TetraLogic Pharmaceuticals Corporation, in January 2006 and maintains its headquarters in Malvern, Pennsylvania.
Harga Saham
$0.00004
Terakhir disinkronkan: 2026-08-11
Kapitalisasi Pasar
$979.00
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-60.00%
Negara
US
Perdagangan TetraLogic Pharmaceuticals Corporation (TLOG)

Kategori

Riwayat hasil dividen untuk TetraLogic Pharmaceuticals Corporation (TLOG)
Hasil dividen (TTM) dari TetraLogic Pharmaceuticals Corporation (simbol saham: TLOG) per 2026: 0
Rata-rata hasil dividen selama 5 tahun terakhir: 0.00%
Riwayat hasil dividen untuk TetraLogic Pharmaceuticals Corporation (TLOG) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Hasil dividen (TTM) untuk perusahaan serupa atau pesaing